| Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 … P Jault, T Leclerc, S Jennes, JP Pirnay, YA Que, G Resch, AF Rousseau, ... The Lancet Infectious Diseases 19 (1), 35-45, 2019 | 718 | 2019 |
| Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials M Merabishvili, JP Pirnay, G Verbeken, N Chanishvili, M Tediashvili, ... PloS one 4 (3), e4944, 2009 | 585 | 2009 |
| Direct detection and identification of Pseudomonas aeruginosa in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane … D De Vos, A Lim Jr, JP Pirnay, M Struelens, C Vandenvelde, ... Journal of clinical microbiology 35 (6), 1295-1299, 1997 | 346 | 1997 |
| Engineered endolysin-based “Artilysins” to combat multidrug-resistant gram-negative pathogens Y Briers, M Walmagh, V Van Puyenbroeck, A Cornelissen, W Cenens, ... MBio 5 (4), 10.1128/mbio. 01379-14, 2014 | 341 | 2014 |
| The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure? JP Pirnay, D De Vos, G Verbeken, M Merabishvili, N Chanishvili, ... Pharmaceutical research 28, 934-937, 2011 | 325 | 2011 |
| Pseudomonas aeruginosa Population Structure Revisited JP Pirnay, F Bilocq, B Pot, P Cornelis, M Zizi, J Van Eldere, P Deschaght, ... PloS one 4 (11), e7740, 2009 | 312 | 2009 |
| The magistral phage JP Pirnay, G Verbeken, PJ Ceyssens, I Huys, D De Vos, C Ameloot, ... Viruses 10 (2), 64, 2018 | 297 | 2018 |
| Experimental phage therapy of burn wound infection: difficult first steps T Rose, G Verbeken, D De Vos, M Merabishvili, M Vaneechoutte, ... International journal of burns and trauma 4 (2), 66, 2014 | 246 | 2014 |
| Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—a case report S Jennes, M Merabishvili, P Soentjens, KW Pang, T Rose, E Keersebilck, ... Critical Care 21, 1-3, 2017 | 238 | 2017 |
| Quality and safety requirements for sustainable phage therapy products JP Pirnay, BG Blasdel, L Bretaudeau, A Buckling, N Chanishvili, JR Clark, ... Pharmaceutical research 32, 2173-2179, 2015 | 238 | 2015 |
| Molecular Epidemiology of Pseudomonas aeruginosa Colonization in a Burn Unit: Persistence of a Multidrug-Resistant Clone and a Silver Sulfadiazine-Resistant … JP Pirnay, D De Vos, C Cochez, F Bilocq, J Pirson, M Struelens, ... Journal of clinical microbiology 41 (3), 1192-1202, 2003 | 235 | 2003 |
| FpvB, an alternative type I ferripyoverdine receptor of Pseudomonas aeruginosa B Ghysels, BTM Dieu, SA Beatson, JP Pirnay, UA Ochsner, ML Vasil, ... Microbiology 150 (6), 1671-1680, 2004 | 213 | 2004 |
| Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa Y Briers, M Walmagh, B Grymonprez, M Biebl, JP Pirnay, V Defraine, ... Antimicrobial agents and chemotherapy 58 (7), 3774-3784, 2014 | 212 | 2014 |
| Global Pseudomonas aeruginosa biodiversity as reflected in a Belgian river JP Pirnay, S Matthijs, H Colak, P Chablain, F Bilocq, J Van Eldere, ... Environmental microbiology 7 (7), 969-980, 2005 | 195 | 2005 |
| Effects of Sequential and Simultaneous Applications of Bacteriophages on Populations of Pseudomonas aeruginosa In Vitro and in Wax Moth Larvae AR Hall, D De Vos, VP Friman, JP Pirnay, A Buckling Applied and environmental microbiology 78 (16), 5646-5652, 2012 | 177 | 2012 |
| Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates JP Pirnay, DD Vos, D Mossialos, A Vanderkelen, P Cornelis, M Zizi Environmental microbiology 4 (12), 872-882, 2002 | 170 | 2002 |
| Identification of new, conserved, non‐ribosomal peptide synthetases from fluorescent pseudomonads involved in the biosynthesis of the siderophore pyoverdine D Mossialos, U Ochsner, C Baysse, P Chablain, JP Pirnay, N Koedam, ... Molecular microbiology 45 (6), 1673-1685, 2002 | 164 | 2002 |
| Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium L Freschi, J Jeukens, I Kukavica-Ibrulj, B Boyle, MJ Dupont, J Laroche, ... Frontiers in microbiology 6, 1036, 2015 | 160 | 2015 |
| Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review S Uyttebroek, B Chen, J Onsea, F Ruythooren, Y Debaveye, D Devolder, ... The Lancet Infectious Diseases 22 (8), e208-e220, 2022 | 154 | 2022 |
| Pseudomonas aeruginosa displays an epidemic population structure JP Pirnay, D De Vos, C Cochez, F Bilocq, A Vanderkelen, M Zizi, ... Environmental Microbiology 4 (12), 898-911, 2002 | 153 | 2002 |
